You are here

MSC-based Combo Promotes Wound Healing

The development of chronic diabetic ulcers can lead to amputations, and, importantly, the current standard of care results in the healing of only 30% of patients. Now, a new STEM CELLS Translational Medicine article from the lab of R. Rivkah Isseroff (University of California, Davis, Sacramento, CA, USA) describes the development of a bioengineered scaffold containing hypoxia‐preconditioned, allogeneic human mesenchymal stem cells (MSCs) combined with a beta‐adrenergic antagonist to treat wounds in diabetic mice. Yang et al. report that this optimized treatment approach provides promising results of improved healing and decreased inflammation in diabetic wounds. Overall, this unique approach provides significant, preclinical evidence supporting the translation of this MSC‐based treatment as a therapy for patients with chronic wounds.